Quest Diagnostics Incorporated $DGX Holdings Increased by Sumitomo Mitsui DS Asset Management Company Ltd

Posted by Francis Steltz on Oct 22nd, 2026

Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 47.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,513 shares of the medical research company’s stock after acquiring an additional 7,514 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Quest Diagnostics were worth $5,480,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. CWA Asset Management Group LLC acquired a new stake in Quest Diagnostics in the third quarter valued at about $4,121,000. Greg Jennings LLC purchased a new stake in Quest Diagnostics in the 3rd quarter valued at approximately $764,000. Clark Wealth Partners boosted its holdings in Quest Diagnostics by 14,182.4% in the 3rd quarter. Clark Wealth Partners now owns 2,428 shares of the medical research company’s stock valued at $566,000 after purchasing an additional 2,411 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in Quest Diagnostics by 2.1% in the 3rd quarter. V Square Quantitative Management LLC now owns 4,185 shares of the medical research company’s stock valued at $975,000 after purchasing an additional 87 shares in the last quarter. Finally, Community Financial Services Group LLC acquired a new position in Quest Diagnostics during the 3rd quarter worth approximately $3,625,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Robert W. Baird increased their target price on Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. UBS Group reissued a “neutral” rating and issued a $250.00 price target on shares of Quest Diagnostics in a report on Monday. Weiss Ratings upgraded Quest Diagnostics from a “buy (a-)” rating to a “buy (a)” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. upped their price objective on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $243.64.

Read Our Latest Research Report on DGX

Insider Activity

In related news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total value of $2,427,200.00. Following the sale, the chief executive officer owned 122,423 shares in the company, valued at $29,714,510.56. This represents a 7.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the sale, the senior vice president owned 10,335 shares in the company, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 34,277 shares of company stock worth $8,316,493. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Stock Up 0.7%

Shares of NYSE DGX opened at $238.78 on Thursday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. Quest Diagnostics Incorporated has a 52 week low of $171.18 and a 52 week high of $248.84. The firm has a 50-day moving average price of $237.36 and a 200 day moving average price of $216.31. The stock has a market capitalization of $26.35 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter in the previous year, the firm earned $2.62 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. Equities research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th were given a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date was Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

About Quest Diagnostics

(Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.